Could a probiotic slow type 1 diabetes? new trial tests Lp299v
NCT ID NCT04335656
First seen Mar 25, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This phase 2 trial is testing whether a probiotic called Lactiplantibacillus plantarum (Lp299v) can reduce inflammation and help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. The study involves 60 participants aged 3 to 45 who were diagnosed within the last 100 days. Half will take the probiotic daily for 6 months, and the other half will take a placebo, with researchers measuring changes in inflammation and insulin production over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lactiplantibacillus plantarum (Lp299v) probiotic
What this could lead to
If it works, this could point toward a simple probiotic supplement to help preserve insulin-making cells and reduce inflammation in people newly diagnosed with type 1 diabetes.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply widely. The probiotic may not significantly slow disease progression or reduce inflammation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.